Promise in New Cancer Treatments, for Patients and Investors
Key players in the pharmaceuticals sector are fortifying their moats with emerging immuno-oncology drugs.
Morningstar’s equity analysts find the U.S. market overall somewhat overvalued, but there are pockets of opportunity for long-term investors. Pharmaceuticals are one of those areas, and some key players in the sector are fortifying their moats with emerging immuno-oncology drugs, as discussed in a recent white paper from Morningstar Research Services.
To explore these opportunities, I spoke with co-author Damien Conover, director of pharmaceutical research. Our conversation took place June 1 and has been edited for length and clarity.
Laura Lallos has a position in the following securities mentioned above: PFE. Find out about Morningstar’s editorial policies.